1. Home
  2. CLLS

as 08-22-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Founded: 1999 Country:
France
France
Employees: N/A City: N/A
Market Cap: 299.0M IPO Year: 2007
Target Price: $4.00 AVG Volume (30 days): 199.3K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.60 EPS Growth: N/A
52 Week Low/High: $1.10 - $3.24 Next Earning Date: 08-04-2025
Revenue: $63,438,000 Revenue Growth: 223.09%
Revenue Growth (this year): -7.49% Revenue Growth (next year): 4.90%

CLLS Daily Stock ML Predictions

Share on Social Networks: